{
    "organizations": [],
    "uuid": "1f58883ac1f510d69db5f72d7278ca93e9768023",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-recipharm-signs-licensing-agreemen/brief-recipharm-signs-licensing-agreement-with-altus-formulation-idUSASM000K2E",
    "ord_in_thread": 0,
    "title": "BRIEF-Recipharm Signs Licensing Agreement with Altus Formulation",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - RECIPHARM AB (PUBL):\n* RECIPHARM AND ALTUS FORMULATION COLLABORATE TO OFFER NOVEL DRUG DELIVERY TECHNOLOGIES FOR VALUE ADDED MEDICINES\n* ‍HAS SIGNED A LICENSING AGREEMENT WITH ALTUS FORMULATION INC​\n* ‍SIGNED A LICENSING AGREEMENT WITH ALTUS FORMULATION INC.​\n* ‍ WILL CO-DEVELOP NEW VALUE ADDED MEDICINES FOR ITS CUSTOMERS UTILISING ALTUS’ PATENTED INTELLITAB™ AND FLEXITAB™ DRUG DELIVERY TECHNOLOGIES.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-05T17:06:00.000+02:00",
    "crawled": "2018-03-06T22:37:25.041+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "recipharm",
        "ab",
        "publ",
        "recipharm",
        "altus",
        "formulation",
        "collaborate",
        "offer",
        "novel",
        "drug",
        "delivery",
        "technology",
        "value",
        "added",
        "medicine",
        "signed",
        "licensing",
        "agreement",
        "altus",
        "formulation",
        "licensing",
        "agreement",
        "altus",
        "formulation",
        "new",
        "value",
        "added",
        "medicine",
        "customer",
        "utilising",
        "altus",
        "patented",
        "drug",
        "delivery",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}